Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age.
Recent reports suggest that breakthrough varicella may be more common in children when the Oka/Merck varicella vaccine is given at 12-14 months of age than when it is given at older ages. An analysis of 5 postlicensure clinical trials with this vaccine was conducted to evaluate immune response relative to the age of the vaccine recipient. In 5 clinical trials, 3771 children, 12 through 23 months of age with no history of varicella, received an injection of varicella vaccine. Varicella-zoster virus (VZV) antibody was measured 6 weeks postvaccination by glycoprotein enzyme-linked immunosorbent assay (gpELISA), an assay that correlates with neutralizing antibody. Endpoints evaluated were the response rate (percent of subjects with VZV antibody > or =5 gpELISA units/mL, a titer shown to correlate with protection) and geometric mean titer (GMT) of VZV antibody. Each endpoint was compared across 3 age groups (12-14, 15-17, and 18-23 months of age). Response rates by initial VZV serostatus were evaluated for children vaccinated at 12-14 months of age to assess whether maternal antibody had an impact on the immune response. The response rates were similar among 12-14, 15-17, and 18-23 month olds (93.8, 90.8, and 93.1%, respectively); GMTs were significantly higher among the 12-14 month olds (15.1, 13.5, and 13.7 gpELISA units/mL, respectively). Among children 12-14 months of age, response rates and GMTs were similar regardless of their prevaccination VZV serostatus. Oka/Merck varicella vaccine is highly immunogenic when given to children 12-14 months of age. The immunogenicity profile is similar to that of children 15-17 and 18-23 months of age. The presence of low titers of VZV antibody before vaccination did not influence vaccine response in 12-14 month olds. These results support current recommendations for universal varicella vaccination beginning at 12 months of age.